Cargando…
Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide
An understanding of the interaction between the antibody and its targeted antigen and knowing of the epitopes are critical for the development of monoclonal antibody drugs. Complement factor H (CFH) is implied to play a role in tumor growth and metastasis. An autoantibody to CHF is associated with a...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566401/ https://www.ncbi.nlm.nih.gov/pubmed/31130605 http://dx.doi.org/10.3390/ijms20102568 |
_version_ | 1783426844076277760 |
---|---|
author | Yang, Bing Lin, Shu-Jian Ren, Jia-Yi Liu, Tong Wang, Yue-Ming Li, Cheng-Ming Xu, Wen-Wen He, You-Wen Zheng, Wei-Hong Zhao, Jian Yuan, Xiao-Hui Liao, Hua-Xin |
author_facet | Yang, Bing Lin, Shu-Jian Ren, Jia-Yi Liu, Tong Wang, Yue-Ming Li, Cheng-Ming Xu, Wen-Wen He, You-Wen Zheng, Wei-Hong Zhao, Jian Yuan, Xiao-Hui Liao, Hua-Xin |
author_sort | Yang, Bing |
collection | PubMed |
description | An understanding of the interaction between the antibody and its targeted antigen and knowing of the epitopes are critical for the development of monoclonal antibody drugs. Complement factor H (CFH) is implied to play a role in tumor growth and metastasis. An autoantibody to CHF is associated with anti-tumor cell activity. The interaction of a human monoclonal antibody Ab42 that was isolated from a cancer patient with CFH polypeptide (pCFH) antigen was analyzed by molecular docking, molecular dynamics (MD) simulation, free energy calculation, and computational alanine scanning (CAS). Experimental alanine scanning (EAS) was then carried out to verify the results of the theoretical calculation. Our results demonstrated that the Ab42 antibody interacts with pCFH by hydrogen bonds through the Tyr315, Ser100, Gly33, and Tyr53 residues on the complementarity-determining regions (CDRs), respectively, with the amino acid residues of Pro441, Ile442, Asp443, Asn444, Ile447, and Thr448 on the pCFH antigen. In conclusion, this study has explored the mechanism of interaction between Ab42 antibody and its targeted antigen by both theoretical and experimental analysis. Our results have important theoretical significance for the design and development of relevant antibody drugs. |
format | Online Article Text |
id | pubmed-6566401 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65664012019-06-17 Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide Yang, Bing Lin, Shu-Jian Ren, Jia-Yi Liu, Tong Wang, Yue-Ming Li, Cheng-Ming Xu, Wen-Wen He, You-Wen Zheng, Wei-Hong Zhao, Jian Yuan, Xiao-Hui Liao, Hua-Xin Int J Mol Sci Article An understanding of the interaction between the antibody and its targeted antigen and knowing of the epitopes are critical for the development of monoclonal antibody drugs. Complement factor H (CFH) is implied to play a role in tumor growth and metastasis. An autoantibody to CHF is associated with anti-tumor cell activity. The interaction of a human monoclonal antibody Ab42 that was isolated from a cancer patient with CFH polypeptide (pCFH) antigen was analyzed by molecular docking, molecular dynamics (MD) simulation, free energy calculation, and computational alanine scanning (CAS). Experimental alanine scanning (EAS) was then carried out to verify the results of the theoretical calculation. Our results demonstrated that the Ab42 antibody interacts with pCFH by hydrogen bonds through the Tyr315, Ser100, Gly33, and Tyr53 residues on the complementarity-determining regions (CDRs), respectively, with the amino acid residues of Pro441, Ile442, Asp443, Asn444, Ile447, and Thr448 on the pCFH antigen. In conclusion, this study has explored the mechanism of interaction between Ab42 antibody and its targeted antigen by both theoretical and experimental analysis. Our results have important theoretical significance for the design and development of relevant antibody drugs. MDPI 2019-05-25 /pmc/articles/PMC6566401/ /pubmed/31130605 http://dx.doi.org/10.3390/ijms20102568 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yang, Bing Lin, Shu-Jian Ren, Jia-Yi Liu, Tong Wang, Yue-Ming Li, Cheng-Ming Xu, Wen-Wen He, You-Wen Zheng, Wei-Hong Zhao, Jian Yuan, Xiao-Hui Liao, Hua-Xin Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide |
title | Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide |
title_full | Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide |
title_fullStr | Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide |
title_full_unstemmed | Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide |
title_short | Molecular Docking and Molecular Dynamics (MD) Simulation of Human Anti-Complement Factor H (CFH) Antibody Ab42 and CFH Polypeptide |
title_sort | molecular docking and molecular dynamics (md) simulation of human anti-complement factor h (cfh) antibody ab42 and cfh polypeptide |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566401/ https://www.ncbi.nlm.nih.gov/pubmed/31130605 http://dx.doi.org/10.3390/ijms20102568 |
work_keys_str_mv | AT yangbing moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide AT linshujian moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide AT renjiayi moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide AT liutong moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide AT wangyueming moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide AT lichengming moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide AT xuwenwen moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide AT heyouwen moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide AT zhengweihong moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide AT zhaojian moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide AT yuanxiaohui moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide AT liaohuaxin moleculardockingandmoleculardynamicsmdsimulationofhumananticomplementfactorhcfhantibodyab42andcfhpolypeptide |